Testis Tumor Markers: How Accurate are They?
- 30 April 1981
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 125 (5) , 661-663
- https://doi.org/10.1016/s0022-5347(17)55155-1
Abstract
Initial reports on the usefulness of radioimmunoassays for the .beta. chain of human chorionic gonadotropin and for .alpha.-fetoprotein suggested that these 2 tests would detect metastatic nonseminomatous testicular cancer in 93% of the cases. In a review of 30 patients with stages 2 and 3 nonseminomatous testicular cancer, a 20% falsely negative rate was found for these serum assays. In all of these cases the .beta.-human chorionic gonadotropin and .alpha.-fetoprotein levels were simultaneously negative despite proved existence of metastatic disease.This publication has 5 references indexed in Scilit:
- Staging of Early Nonseminomatous Germ‐Cell Testicular CancerCancer, 1980
- Relevance of Biochemical Tumor Markers and Lymphadenectomy in Management of Non-Seminomatous Testis Tumors: Current PerspectiveJournal of Urology, 1980
- Is SP-1 a marker for testicular cancer?Urology, 1980
- Improved Chemotherapy in Disseminated Testicular CancerJournal of Urology, 1977
- The use of a radioimmunoassay for alpha-fetoprotein in the diagnosis of malignancyCancer, 1974